Back to top

messenger-rna: Archive

Sundeep Ganoria

CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?

The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

VRTXPositive Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change

Sundeep Ganoria

Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?

Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA stock.

GSKNegative Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna Poised to Report Q4 Earnings: Is a Beat in the Cards?

When MRNA reports fourth-quarter earnings, investors will likely focus on pipeline updates.

MRKPositive Net Change MRNAPositive Net Change SRPTNegative Net Change CRSPNegative Net Change

Zacks Equity Research

PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor

A Bloomberg article suggests activist investor Starboard cut Pfizer some slack by not nominating any director on the company's board this year.

PFEPositive Net Change CTMXNegative Net Change CSTLNegative Net Change ERASNegative Net Change

Zacks Equity Research

Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab

MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for additional subtypes of pandemic influenza.

MRNAPositive Net Change NVAXPositive Net Change CVACPositive Net Change

Sundeep Ganoria

How to Play Moderna Stock After the Recent Sales Guidance Cut

Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.

GSKNegative Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna Stock Plummets 17% on 2025 Sales Guidance Slash

The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative.

MRKPositive Net Change MRNAPositive Net Change CTMXNegative Net Change CSTLNegative Net Change